OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial.
Read more at prnewswire.comPhotocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here